Discovery and application of non-competitive antagonistic histamine H4 receptor natural antagonist
Through the non-competitive antagonism of cryptanshinone in salvia, the problem of major side effects of existing H4 receptor antagonists is solved, and a highly active, non-competitive natural compound is provided for the treatment of multiple An inflammatory disease.
Patent Information
- Application Number
- CN202411312861.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing H4 receptor antagonists have great side effects in the treatment of diseases such as inflammatory bowel disease, and most of them are competitive antagonists, lacking highly active non-competitive natural compounds.
It was discovered and verified that the natural compound cryptanshinone in Salvia miltiorrhiza has inhibitory activity on histamine H4 receptor. Its H4 receptor antagonism activity was verified through the label-free cell integration pharmacology platform and high-throughput real-time fluorescence detection system, demonstrating non-competitive antagonism. effect.
Crypthanshinone has shown good H4 receptor inhibitory activity, and has potential drug development prospects for the treatment of diseases such as inflammatory bowel disease, allergic rhinitis, atopic rhinitis, allergic asthma, rheumatoid arthritis, etc., and has fewer side effect.
Smart Images

Figure CN118924769A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the discovery and application of targeted active molecules in natural products, specifically the discovery and application of cryptotanshinone, a natural antagonist that inhibits H4 receptor activity. The application includes the treatment of one or more of inflammatory diseases such as inflammatory bowel disease, allergic rhinitis, atopic rhinitis, allergic asthma, rheumatoid arthritis, neuropathic inflammation, etc. Background Art
[0002] The histamine 4 receptor (H4R) is the last histamine receptor subtype discovered. It mainly causes inflammatory responses after activation. H4R is mainly expressed in immune system cells and is a Gαi / o coupled receptor. It was not discovered until 2000. (Oda, T., et al., 2000. Molecular cloning and characterization of a noveltype of histamine receptor preferentially expressed in leukocytes. J Biol Chem. 275, 36781-36786.) Experimental and clinical studies have shown that H4R antagonists can effectively treat immune response-related symptoms such as itching and inflammation (Schaper-Gerhardt, K., et al., 2020. The role of the histamineh(4) receptor in atopic dermatitis and psoriasis. Br J Pharmacol. 177, 490-502;Schirmer, B., et al., 2021. The function of the histamine h4 receptor ininflammatory and inflammation-associated diseases of the gut. Int J Mol Sci.22, 11.). For example, JNJ7777120 is the first potent and selective H4R antagonist with anti-inflammatory properties, but it has a short in vivo half-life and low adrenocortical toxicity in rat and dog models, so it cannot enter clinical studies (Thurmond, RL, et al., 2017. Clinical development of histamine h(4) receptor antagonists. Handb Exp Pharmacol. 241, 301-320.).JNJ39758979 is similar in structure to JNJ7777120, and has anti-inflammatory and antipruritic activities, but can induce agranulocytosis (Murata, Y., et al., 2015. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a h4r-antagonist (jnj-39758979) in japanese adults with moderate atopic dermatitis. J Dermatol. 42, 129-139.). Many H4R antagonists have been developed and have therapeutic effects on inflammatory bowel disease (IBD) and atopic dermatitis (AD), but adverse side effects limit their use. Therefore, the discovery of new H4 receptor antagonists is of great significance.
[0003] Natural products are an important source of active compounds with the advantages of few side effects and high structural diversity, and can be developed into therapeutic drugs (Baker, DD, et al., 2004. Small-molecule natural products: Newstructures, new activities. Current Opinion in Biotechnology. 15, 576-583.). Currently, about half of the drugs are related to natural products (Newman, DJ, et al., 2020. Naturalproducts as sources of new drugs over the nearly four decades from 01 / 1981 to09 / 2019. Journal of Natural Products. 83, 770-803.). It has been reported that some H4R antagonists are derived from natural products, such as curcumin, demethoxycurcumin and bis(4-hydroxy-cinnamyl)methane extracted from turmeric (Frank, A., et al., 2017. From medicinal plant extracts to defined chemical compounds targeting the histamine h(4) receptor: Curcuma longa in thetreatment of inflammation. Inflamm Res. 66, 923-929.), and ascorbic acid and anthocyanidin-3-glycoside extracted from bayberry (Do, NQ, et al., 2021. Anti-allergic effects ofmyrciaria dubia (camu-camu) fruit extract by inhibiting histamine h1 and h4receptors and histidine decarboxylase in rbl-2h3 cells. Antioxidants (Basel).11, 1.). Quercetin has anti-inflammatory and antipruritic effects and can also inhibit the Ca2+-induced by H4 receptor agonist (4-methylhistamine). 2+The concentration of quercetin increases (Yang, CC, et al., 2021. Quercetin inhibits histamine-induced calcium influx in human keratinocyte via histamine h4 receptors. IntImmunopharmacol. 96, 107620.). However, the activity is poor and all inhibit H4 receptors in a competitive manner. Therefore, it is hoped to find new highly active non-competitive H4R antagonists from natural products.
[0004] Cryptotanshinone is a bioactive component of Salvia miltiorrhiza. It has been intensively studied as a medicinally active compound and has shown anti-inflammatory and immunomodulatory pharmacological activities. Cryptotanshinone can improve a variety of inflammatory immune diseases, such as ulcerative colitis (UC) and atopic dermatitis (AD). The pathogenesis of atopic dermatitis (AD) is that the antigen / immunoglobulin IgE complex binds to the high-affinity receptor FcεRl on the surface of mast cells, leading to excessive activation of mast cells and secretion of excessive pro-inflammatory mediators (Buyanravjikh, S., et al., 2018. Cryptotanshinone inhibits ige-mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mast cells. Mol Med Rep. 18, 1095-1103.). In a dinitrobenzene-induced AD-like skin disease mouse model, cryptotanshinone not only inhibited IgE / antigen complexes, but also effectively attenuated the secretion of proinflammatory cytokines and the infiltration of immune cells into skin lesions (Buyanravjikh, S., et al., 2018. Cryptotanshinone inhibits ige-mediated degranulation through inhibitionof spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mastcells. Mol Med Rep. 18, 1095-1103.). Similarly, cryptotanshinone can improve UC in both in vitro and in vivo models, although the exact pathogenesis of UC is still unclear. In the dextran sulfate sodium (DSS)-induced UC mouse model, pathological manifestations include weight loss, rectal bleeding, increased disease activity index (DAI), shortened colon length, mucosal necrosis, edema, glandular destruction, inflammatory cell infiltration, and significantly increased levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) (Min, X., et al., 2020. Cryptotanshinone protects dextran sulfate sodium-inducedexperimental ulcerative colitis in mice by inhibiting intestinalinflammation. Phytother Res. 34, 2639-2648.).Cryptotanshinone can significantly improve these pathological changes in the UC model and almost completely inhibit the TLR4 / p38MAPK / NF-κB pathway, which plays an important role in the pathogenesis of inflammatory bowel disease (IBD) (Min, X., et al., 2020. Cryptotanshinone protects dextransulfate sodium-induced experimental ulcerative colitis in mice by inhibitingintestinal inflammation. Phytother Res. 34, 2639-2648.).
[0005] Cryptotanshinone has anti-inflammatory pharmacological activity, and the function of cryptotanshinone is similar to that of H4 receptor antagonist, but there is currently no report that cryptotanshinone has antagonistic activity on H4 receptor. Summary of the invention
[0006] The purpose of the present invention is to provide a compound having histamine H4 receptor inhibitory activity and its application. Specifically, one of the purposes of the present invention is to provide a compound having histamine H4 receptor inhibitory activity, namely cryptotanshinone. The second purpose of the present invention is to provide the application of the compound cryptotanshinone, that is, to provide the clinical application range of this compound, including clinical treatment of one or more inflammatory diseases such as inflammatory bowel disease, allergic rhinitis, atopic rhinitis, allergic asthma, rheumatoid arthritis, neuropathic inflammation, etc., to provide a basis for subsequent drug development.
[0007] Chemical name: (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-phenanthro (1,2-b) furan-10,11-dione, orange-brown powder, molecular formula: C 19 H 22 O3, molecular weight 298.38.
[0008] The activity of cryptotanshinone in the present invention is specifically reflected in the inhibitory effect on H4 receptors on CHO-K1-H4R cell lines. It shows good H4 receptor antagonistic activity on label-free integrated pharmacology platform, high-throughput real-time fluorescence detection system platform, and molecular docking simulation platform.
[0009] Advantages of the present invention: The present invention discovered for the first time the histamine H4 receptor antagonist activity of cryptotanshinone, and its good H4 receptor inhibitory activity can be used to prepare drugs for treating, preventing, inhibiting or alleviating diseases regulated by H4 receptor active ligands, and has good development prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 A DMR responses of H4 receptor to different concentrations of histamine on a label-free cell-integrated pharmacology platform.
[0011] B Concentration-dependent DMR responses of H4 receptor to different concentrations of histamine and JNJ7777120 on a label-free cell-integrated pharmacology platform.
[0012] Figure 2 A Real-time DMR signal of CHO-K1-H4R cells after treatment with 40 μM cryptotanshinone on a label-free cell-integrated pharmacology platform B Real-time DMR signal of 1.5 μM histamine in CHO-K1-H4R cells after pretreatment with 40 μM cryptotanshinone on a label-free cell-integrated pharmacology platform Figure 3 A. Cryptotanshinone reduces histamine-induced DMR signals in a concentration-dependent manner on a label-free cell-integrated pharmacological platform B Cryptotanshinone concentration-dependent inhibition of histamine-induced Ca2+ expression on a high-throughput real-time fluorescence detection platform 2+ Signal C Western blot analysis of the thermal stability of H4R protein in the presence (+) or absence (−) of 20 μM cryptotanshinone.
[0013] D Cell viability of CHO-Gα15-H4R cells after 24 h of cryptotanshinone treatment Figure 4 Changes of DMR amplitude with concentration of histamine in A431 cells, HEK293-H2R cells and HEK293-H3R cells B. Changes of DMR amplitude with histamine concentration in A431 cells, HEK293-H2R cells and HEK293-H3R cells (pre-treatment with cryptotanshinone) Figure 5 A Histamine DMR response signals in the presence of different concentrations of cryptotanshinone on a label-free cell-integrated pharmacology platform B Schild analysis of cryptotanshinone on the label-free cell-integrated pharmacology platform Figure 6 A AlphaFold (AF) predicted the three-dimensional structure of H4 receptor B Prediction of H4 receptor allosteric binding sites (Site 1 and Site 2) using Sitemap, Fpocket and CavityPlus programs 2D and 3D schematic diagrams of the interaction between C cryptotanshinone and Site 1 2D and 3D schematic diagram of the interaction between D-cryptotanshinone and Site 2 E RMSD diagram of the cryptotanshinone-site 1 complex RMSD plot of cryptotanshinone-site 2 in complex F Figure 7 Molecular dynamics simulation of cryptotanshinone-site 1 complex A Molecular dynamics simulation of the cryptotanshinone-site 2 complex Figure 8 MM-GBSA with cryptotanshinone binding to Site 1 and Site 2 Fig. 9 Cryptotanshinone structure DETAILED DESCRIPTION
[0014] The present invention is described below by means of specific embodiments, but the present invention is not limited thereto.
[0015] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and biological materials described are commercially available unless otherwise specified.
[0016] Example 1 Establishment of H4 receptor high-throughput screening model Chinese hamster ovary CHO-K1-H4R cells (stable transfection with H4R) were obtained from Nanjing GenScript Biotechnology Co., Ltd. CHO-K1-H4R cells were cultured in F12K medium supplemented with 10% FBS, 100 μg / mL hygromycin B, 400 μg / mL G418, 50 μg / mL penicillin, and 100 μg / mL streptomycin at 37°C in air / 5% CO2.
[0017] The DMR signals of histamine and JNJ7777120 on the H4 receptor were measured using a label-free cell-integrated pharmacology technology platform. The test method is as follows: CHO-K1-H4R cells were seeded at a density of 15,000 cells per well in Epic 384-well biosensor microplates. Cells were cultured in complete medium for 12-16 h to form a monolayer with a confluency of approximately 95%. The medium was replaced with 1× HBSS buffer (pH 7.4) containing 10 mM HEPES 1 h before measurement. For agonist experiments, a 2 min baseline was established, then compounds were added using a multichannel pipette, and the compound-triggered DMR response signal was recorded for 1 h. For desensitization experiments, cells were pretreated with compounds for 1 h, and then the H4R agonist histamine (EC 80 ), and the histamine-induced DMR signal was monitored for 1 h. Cells were pretreated with H4R antagonists or test compounds for 1 h, and then the indicated concentrations of histamine (EC 80), monitor the histamine-induced signal for 1 h. Finally, the obtained signal response was converted into data export using Imager Beta v3.7 software, and the exported data was processed using Microsoft Excel 2016 and GraphPad Prism 9 software.
[0018] A high-throughput screening model for H4R was established in CHO-K1-H4R cells using label-free cell integration technology, and the model was evaluated using known H4R agonists histamine and antagonists JNJ7777120. Three forms of DMR experiments were performed: agonistic experiments, desensitization experiments, and antagonistic experiments. In the agonistic experiments, histamine triggered a concentration-dependent DMR response, and EC 50 The value was 0.61± 0.09 μM ( Figure 1 A and B). In the desensitization experiment, the early addition of histamine made the cells sensitive to the later addition of 1.5 μM (EC 80 ) Histamine desensitization, IC 50 The value was 0.51±0.08 μM ( Figure 1 B). In the antagonist assay, JNJ7777120 inhibited histamine signaling in a concentration-dependent manner, with an IC 50 The value was 1.31 ± 0.27 μM ( Figure 1 B). These results indicate that the H4 receptor in CHO-K1-H4R cells is functional and this model can be used for subsequent high-throughput screening to identify H4R antagonists.
[0019] Example 2 Detection of real-time DMR signal of cryptotanshinone antagonizing H4 receptor using H4 receptor target model The DMR response signal of cryptotanshinone on H4 receptor was determined using a label-free cell-integrated pharmacology technology platform. The test method is as follows: Cryptotanshinone was tested by two-step DMR analysis using the developed CHO-K1-H4R high-throughput screening model. The first step recorded the DMR signal triggered by cryptotanshinone at a concentration of 40 μM. The second step recorded the DMR signal induced by histamine after cryptotanshinone pretreatment. Cryptotanshinone caused negligible DMR signals in the first step ( Figure 2 A), in the second step, the signal of the endogenous ligand histamine is significantly inhibited ( Figure 2 B), which supports the antagonist screening criteria, making it an H4 receptor antagonist drug candidate.
[0020] Example 3 Concentration-dependent DMR of Cryptotanshinone Signal The activity of cryptotanshinone on the H4 receptor was determined using a label-free cell-integrated pharmacology technology platform. The test method is as follows: CHO-K1-H4R cells were seeded at a density of 15,000 cells per well in Epic 384-well biosensor microplates. Cells were cultured in complete medium for 12-16 h to form a monolayer with a confluency of approximately 95%. The medium was replaced with 1× HBSS buffer (pH 7.4) containing 10 mM HEPES for 1 h before measurement. Cells were pretreated with cryptotanshinone for 1 h, and then the H4R agonist histamine (EC 80 ), and the histamine-induced DMR signal was monitored for 1 h. The results showed that cryptotanshinone completely blocked the histamine-induced DMR signal in a concentration-dependent manner, and IC 50 The value was 11.68 ± 1.30 μM ( Figure 3 A).
[0021] Example 4 Concentration dependence of cryptotanshinone on Ca 2+ Signal The activity of cryptotanshinone on the H4 receptor was determined using a high-throughput real-time fluorescence detection and analysis platform. The test method is as follows: CHO-K1-H4R cells were seeded at a density of 60,000 cells per well in a 96-well plate pre-coated with poly-D-lysine. After incubation at 37 °C overnight, the cells were starved for 24 h. After discarding the culture medium in the cell plate, calcium-6 dye prepared in a buffer solution with pH = 7.4 was added and incubated in an incubator at 37 °C for 1.5 h. The sample solution to be tested was added to two new 96-well dispensing plates (plate A and plate B) in a pre-designed arrangement. Plates A and B, special gun tips, and special 96-well plates containing cells were placed in the corresponding positions of the high-throughput real-time fluorescence detection (FLIPR), and the system was programmed to automatically add drugs to the cells. Ca 2+ The emission wavelength of the concentration detection was 520 nm and the excitation wavelength was 488 nm. The data were expressed as relative fluorescence units (RFU) over time. The antagonistic activity was verified by FLIPR experiment. Cryptotanshinone inhibited histamine-induced Ca 2+ Fluorescence signal, IC 50 The value was 41.68 ± 3.17 μM ( Figure 3 B).
[0022] Example 5 Cellular Thermal Shift (CTS) Assay CHO-Gα15-H4R cells were seeded in 10 cm cell culture dishes. When the cell confluence reached about 95%, the cells were treated with 20 μM cryptotanshinone or DMSO for 1 h, then scraped and suspended in 600 μL PBS (1× PI). The treatment group was treated with 20 μM cryptotanshinone on the basis of the control group. The obtained cell suspension was divided into 40 μL aliquots, each of which was heated at the specified temperature (37°C, 42°C, 47°C, 52°C, 57°C and 62°C) for 3 min in a 0.2 mL PCR tube and then quickly cooled on ice. After that, the heat-treated cell suspension was lysed with a lysis buffer containing 0.09 M NaCl, 6 mM HEPES and 0.6% Triton™X-100 for 30 min. After centrifugation at 12,000 rpm at 4°C for 10 min, the supernatant was mixed with 1× loading buffer (heated to 95°C for 10 min). The protein content was separated by 12% SDS-PAGE and then transferred to a PVDF membrane using a Bio-Rad system. The PVDF membrane was blocked in TBST buffer (0.1% Tween-20 and 1× PBS) containing 5% skim milk for 1 h and then incubated with the primary antibody in TBST buffer at 4°C overnight. After washing with TBST buffer, the secondary antibody was added and incubated at room temperature for 1 h. After washing with TBST buffer, the color was developed using Super Signal West Pico. The molecular imager ChemiDoc XRS was then used. + (Bio-rad, Hercules, CA, USA) was used to image specific protein bands. The results showed that 20 μM cryptotanshinone bound to H4R and enhanced the thermal stability of H4R protein. At 47°C and 52°C, the amount of undegraded protein in the treatment group was higher than that in the control group ( Figure 3 C).
[0023] Example 6 Cytotoxicity Detection of Cryptotanshinone 10,000 CHO-Gα15-H4R cells were seeded in 96-well plates and incubated overnight. The cells were then treated with compounds for 24 h. Cell viability was assessed using a cell counting kit-8 (CCK-8, Beyotime Biotechnology, China). The absorbance was measured using a microplate reader at 450 nm. The cell viability was calculated relative to the untreated control group. The results showed that 100 μM cryptotanshinone had no cytotoxicity to CHO-Gα15-H4R cells ( Figure 3 D).
[0024] Example 7 Histamine receptor subtype selectivity of cryptotanshinone Human epidermoid carcinoma A431 (endogenously expressing H1R) and human embryonic kidney HEK293 cells were purchased from the Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). CHO-Gα15-H4R cells were cultured in F12K medium supplemented with 10% bovine serum, 100 μg / mL hygromycin B, and 400 μg / mL G418. A431, HEK293-H2R, and HEK293-H3R cells were cultured in DMEM medium supplemented with 10% fetal bovine serum. All cells were cultured at 37°C in air / 5% CO2. When transfecting H2R and H3R, plasmid (8 μg) and Lipofectamine 2000 (24 μL) were diluted with Opti-MEM (750 μL) and then combined into the transfection solution. After standing at room temperature for 15 min, the transfection solution was dropped into a 10 cm HEK293 cell culture dish. 24 h after transfection, HEK293-H2 cells and HEK293-H3R cells were cloned with complete medium containing G418 (600 μg / mL). Stable clones were obtained after 3-4 weeks of antibiotic treatment. CHO-Gα15-H4R cells were seeded at a density of 15,000 cells per well in Epic 384-well biosensor microplates. A431, HEK293-H2R, and HEK293-H3R cells were seeded at a density of 25,000 cells per well. CHO-Gα15-H4R cells were cultured for 12-16 h, and A431, HEK293-H2R, and HEK293-H3R cells were cultured in complete medium for 22-24 h to form monolayers with a confluence of approximately 95%. The medium was replaced with 1× HBSS buffer (pH 7.4) containing 10 mM HEPES 1 h before measurement. DMR assays were performed as previously described. In the agonist experiments, histamine triggered concentration-dependent DMR responses in A431-H1R, HEK293-H2R, and HEK393-H3R. 50 The values were 7.62 ± 0.58 μM, 0.066 ± 0.011 μM and 0.013 ± 0.003 μM, respectively. Figure 4 A). In the antagonist experiment, the histamine signals of the three histamine receptors were only slightly inhibited by 80 μM cryptotanshinone ( Figure 4 B). These results suggest that cryptotanshinone is more selective for H4R than the other three receptor subtypes.
[0025] Example 8 Antagonistic Mechanism of Cryptotanshinone on H4 Receptor In order to characterize the kinetic binding mode of cryptotanshinone on the H4 receptor, a DMR co-stimulation experiment was performed (H4 receptor agonist histamine (EC 80) and different concentrations of cryptotanshinone co-stimulation). The results showed that different concentrations of cryptotanshinone did not cause a rightward shift in the histamine concentration-response curve; on the contrary, when its concentration increased, the compound significantly reduced its maximum response reading ( Figure 5 A). EC of histamine 50 The values also increased with the increase of cryptotanshinone concentration. When the concentration of cryptotanshinone was 0 μM, 1 μM, 10 μM, 25 μM, 50 μM and 100 μM, the EC 50 The values were 0.35 ± 0.05 μM, 0.38 ± 0.06 μM, 0.47 ± 0.07 μM, 1.96 ± 0.27 μM, 12.84 ± 3.16 μM and 55.56 ± 28.01 μM, respectively. Schild analysis showed a slope of 0.38 ( Figure 5 B). In conclusion, cryptotanshinone is a noncompetitive antagonist of H4R.
[0026] Example 9 Molecular docking and dynamic simulation of cryptotanshinone and H4 receptor The sequence and UniProt ID of H4R refer to UniProtKB (https: / / www.uniprot.org / uniprot / Q9H3N8). The three-dimensional structure of H4 receptor was predicted by AlphaFold (AlphaFoldDB Q9H3N8), and three programs were used to predict the binding sites: SiteMap, fpocket, and CavityPlus. Two binding sites (called Site 1 and Site 2) with high site scores or drugability scores predicted by the three programs were selected for molecular docking. The minimized 3D structure of cryptotanshinone was generated using the OPLS-4 force field in the LigPrep module of Schrödinger software (Version 2022-1, Schrödinger, Inc., New York, NY). Molecular docking of cryptotanshinone with Site 1 and Site 2 was performed on Schrödinger using the induced matching docking (IFD) method, respectively. The optimal pose was selected, and the binding free energy / molecular mechanics / generalized Born and binding free energy (MM-GBSA) were calculated using the Prime module. To further evaluate the stability of the ligand-receptor complex, molecular dynamics simulations were performed using the Desmond module for 100 ns. For the cryptotanshinone-Site 1 and cryptotanshinone-Site 2 complexes, the mature SPC model was used to construct periodic boundary conditions, crystal water particles with orthogonal intermittent limiting conditions in a 10 Å buffer, and Na +to neutralize the entire atomic framework. The isothermal and isobaric ensemble (NPT) was used to maintain a constant temperature of 300 K and a constant pressure of 1 bar in the system. The trajectory was maintained at a speed of 10 ps and the frame number was 10,000.
[0027] Using AlphaFold to predict the three-dimensional structure of H4 receptor protein (AlphaFoldDB Q9H3N8) ( Figure 6 A). Given that cryptotanshinone exhibits noncompetitive antagonism on H4 receptors, we used SiteMap, Fpocket, and CavityPlus to predict allosteric binding sites. Two binding sites with higher site scores or drugability scores predicted by the three programs were selected for molecular docking. Figure 6 As shown in B, Site 1 is located in the groove formed by the outward interface between TM3 / 4 / 5, and this site is mainly composed of non-polar aliphatic and aromatic amino acid residues. Site 2 is larger than Site 1, located at the intracellular end of TM2 / 3 / 6 / 7, and is mainly composed of basic amino acid residues. Cryptotanshinone was molecularly docked with Site 1 and Site 2, with docking scores of -7.31 and -7.22, respectively, and MM-GBSA of -46.75 kcal / moL and -56.66 kcal / moL, respectively. Cryptotanshinone interacts with H4 receptor site 1 through hydrophobic interaction, and the key amino acid residues are Val106, Leu107, Val139, Leu142 and Leu181 ( Figure 6 C). In Site 2, there is a hydrogen bond between Arg112 and the carbonyl group of cryptotanshinone ( Figure 6 D).
[0028] The cryptotanshinone-site 1 complex and the cryptotanshinone-site 2 complex were further subjected to 100 ns molecular dynamics (MD) simulations to verify their stability over time. The root mean square deviation (RMSD) plots are shown in Figure 2. Figure 6 E and 6F. In the cryptotanshinone-Site 1 complex, the ligand and receptor tend to be stable after 50 ns. However, in the cryptotanshinone-Site 2 complex, the RMSD of the ligand is sometimes larger than the RMSD of the protein, indicating that the ligand may diffuse from its initial binding site.
[0029] After 100-ns MD, cryptotanshinone formed hydrophobic interactions with Try103 and Val106 at Site 1 ( Figure 7 A); In Site 2, cryptotanshinone forms hydrogen bonds and hydrophobic interactions with Arg49 and his126, respectively ( Figure 7B). In addition, 10 frames are uniformly selected between 80 and 90 ns (frame 8000 to frame 9000) when the simulation is stable, and the MM-GBSA values of the 10 frames are calculated. Figure 8 As shown in Figure 3, the binding of cryptotanshinone to Site 1 has a lower binding free energy within this time window. Therefore, cryptotanshinone is more likely to interact with H4R at Site 1.
Claims
1. A diterpene quinone natural active molecule is cryptotanshinone, characterized in that: It has non-competitive H4 receptor antagonist activity.
2. The active molecule according to claim 1, characterized in that: The IC of the compound on H4R in a label-free cell integrated pharmacology platform and a high-throughput real-time fluorescence detection analysis platform 50 11.68 ± 1.30 μM and 41.68 ± 3.17 μM, respectively.
3. The active molecule according to claim 1, characterized in that: The compound can increase the thermal stability of H4 receptor and is not toxic to normal CHO cells.
4. The active molecule according to claim 1, characterized in that: The compounds are highly selective for H4R compared to the other three histamine receptor subtypes.
5. The active molecule according to claim 1, characterized in that: Different concentrations of the compound did not cause a rightward shift in the concentration-response curve of histamine, an endogenous ligand of the H4 receptor, on a label-free cell-integrated pharmacology platform, and the slope of the Schild analysis was 0.38, indicating that cryptotanshinone non-competitively antagonized the H4 receptor.
6. The active molecule according to claim 1, characterized in that: The compound was molecularly docked with the allosteric site 1 (Site 1) and site 2 (Site 2) of the H4 receptor protein, with docking scores of -7.31 and -7.22, and MM-GBSA of -46.75 kcal / moL and -56.66 kcal / moL, respectively. The compound interacts with Site 1 through hydrophobic interaction, and the key amino acid residues are Val106, Leu107, Val139, Leu142 and Leu181. In Site 2, there is a hydrogen bond between Arg112 and the carbonyl group of cryptotanshinone.
7. The use according to claim 2, characterized in that: The diseases associated with H4 receptor antagonistic activity include the treatment of one or more inflammatory diseases such as inflammatory bowel disease, allergic rhinitis, atopic rhinitis, allergic asthma, rheumatoid arthritis and neuropathic inflammation, or the diseases associated with H4 receptor inhibitory activity include the treatment of one or more cancer diseases such as bladder urothelial carcinoma, breast cancer, endometrial cancer, liver cancer, esophageal cancer and kidney cancer.
8. A medicine and / or health product and / or auxiliary medicine product, which uses one or more of the cryptotanshinone and / or its derivatives as claimed in claim 1 as active ingredients (as H4 receptor antagonists), with or without pharmaceutically or food-acceptable carriers or excipients.
